POSC23 Reductions in Migraine and Headache Days with Quarterly and Monthly Fremanezumab in Adult Patients with Migraine in a US Real-World Setting
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.169
https://www.valueinhealthjournal.com/article/S1098-3015(21)01964-1/fulltext
Section Title :
Section Order :
10935
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01964-1&doi=10.1016/j.jval.2021.11.169